摘要
目的:探讨重组人脑利钠肽辅助治疗心力衰竭合并呼吸衰竭治疗中的效果和安全性。方法:回顾分析2019年4月—2021年4月在我院接受诊治的78例心力衰竭合并呼吸衰竭患者为研究对象,并根据用药方案的不同分为试验组41例和对照组37例。两组均严格遵循中国心力衰竭诊断和治疗指南中的要求对应给予药物,试验组在此基础上增加重组人脑利钠肽,比较两组治疗效果、血清指标、不良反应发生情况及随访结果。结果:试验组治疗总有效率为90.24%,高于对照组的72.97%(P<0.05);试验组外周血清中NT-proBNP水平低于对照组,左室射血分数和24h尿量高于对照组(P<0.05);试验组不良反应发生率与对照组比较,差异无统计学意义(P>0.05);随访1年后,试验组不良事件发生率低于对照组(P<0.05)。结论:重组人脑利钠肽辅助治疗心力衰竭合并呼吸衰竭的效果确切,可改善血清指标,降低不良事件发生风险,且联合用药不增加不良反应发生概率,应用安全性较高。
Objective:To investigate the effect and safety of recombinant human brain natriuretic peptide in the treatment of heart failure and respiratory failure.Methods:A retrospective analysis of 78 patients with heart failure and respiratory failure who were treated in our hospital from April 2019 to April 2021 was conducted.According to the different medication regimens,they were divided into experimental group(41 cases)and control group(37 cases).Both groups were given drugs in strict accordance with the requirements of the Chinese guidelines for the diagnosis and treatment of heart failure.The experimental group added recombinant human brain natriuretic peptide on this basis.The therapeutic effect,serum index,adverse reactions and follow-up results were compared between the two groups.Results:The total effective rate of treatment in the experimental group was 90.24%,which was higher than 72.97%in the control group(P<0.05).The level of NT-proBNP in peripheral serum of the experimental group was lower than that of the control group,and the left ventricular ejection fraction and 24 h urine volume were higher than those of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the experimental group and the control group(P>0.05).After 1 year of follow-up,the incidence of adverse events in the experimental group was lower than that in the control group(P<0.05).Conclusion:Recombinant human brain natriuretic peptide is effective in the adjuvant treatment of heart failure complicated with respiratory failure,which can improve serum indexes and reduce the risk of adverse events.The combination of drugs does not increase the incidence of adverse reactions, and the application safety is high.
作者
焦颖
李冬生
JIAO Ying;LI Dongsheng(Department of Respiratory and Critical Care Medicine,Tianjin Nankai Hospital,Tianjing 300110,China)
出处
《中国药物滥用防治杂志》
CAS
2023年第11期1947-1950,共4页
Chinese Journal of Drug Abuse Prevention and Treatment
关键词
心力衰竭
呼吸衰竭
重组人脑利钠肽
不良事件
Heart failure
Respiratory failure
Recombinant human brain natriuretic peptide
Adverse event
